Hasaabani and Kerm Launch Biosimilars File

The workshop focused on organizing the registration, importation, and distribution of biosimilars in Lebanon, with the aim of protecting patients and ensuring the quality, safety, and efficacy of these medicines. The participants emphasized the importance of adopting international scientific and regulatory standards, based on guidelines from organizations such as the World Health Organization, the European Medicines Agency, and the FDA, while adhering to good manufacturing practices and good clinical practices. Representatives Fadi Karam and Ghassan Hasbani presented a draft law to ensure that the registration process for these medicines is subject to strict standards, along with the establishment of a national registry to regulate substitution procedures. The goal is to broaden access to biosimilars while maintaining safety and quality standards.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل